Clinical Stage IV Cutaneous Melanoma AJCC v8
Oncology·MeSH: Melanoma
Prevalence
75.0 / 100K
Incidence
23.0 / 100K/yr
3 drugs in development·1 company·7 clinical trials
Drug Pipeline by Phase
Phase 3(2)
Phase 2(1)
| Drug | Company |
|---|---|
| hydroxychloroquine | GH Research PLC (GHRS) |
Compare drugs
Frequently asked questions
How many drugs are in development for Clinical Stage IV Cutaneous Melanoma AJCC v8?
BioSniper tracks 3 drugs in development for Clinical Stage IV Cutaneous Melanoma AJCC v8 across 1 company.
How many clinical trials target Clinical Stage IV Cutaneous Melanoma AJCC v8?
There are 7 clinical trials targeting Clinical Stage IV Cutaneous Melanoma AJCC v8 tracked by BioSniper.
What is the prevalence of Clinical Stage IV Cutaneous Melanoma AJCC v8?
The estimated prevalence of Clinical Stage IV Cutaneous Melanoma AJCC v8 is approximately 75.0 per 100,000 population.
Deep-dive into Clinical Stage IV Cutaneous Melanoma AJCC v8
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis